Disruption of IL-21 Signaling Affects T Cell-B Cell Interactions and Abrogates Protective Humoral Immunity to Malaria

Damián Pérez-Mazliah, Dorothy Hui Lin Ng, Ana Paula Freitas do Rosário³, Sarah McLaughlin, Béatris Mastelic-Gavillet⁰, Jan Sodenkamp, Garikai Kushinga, Jean Langhorne*

Division of Parasitology, MRC National Institute for Medical Research (NIMR), London, United Kingdom

³ Current address: Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, São Paulo, Brazil
⁰ Current address: World Health Organization Collaborating Center for Vaccine Immunology, Departments of Pathology-Immunology and Pediatrics, University of Geneva, Geneva, Switzerland.

* jlangho@nimr.mrc.ac.uk

Abstract

Interleukin-21 signaling is important for germinal center B-cell responses, isotype switching and generation of memory B cells. However, a role for IL-21 in antibody-mediated protection against pathogens has not been demonstrated. Here we show that IL-21 is produced by T follicular helper cells and co-expressed with IFN-γ during an erythrocytic-stage malaria infection of Plasmodium chabaudi in mice. Mice deficient either in IL-21 or the IL-21 receptor fail to resolve the chronic phase of P. chabaudi infection and P. yoelii infection resulting in sustained high parasitemias, and are not immune to re-infection. This is associated with abrogated P. chabaudi-specific IgG responses, including memory B cells. Mixed bone marrow chimeric mice, with T cells carrying a targeted disruption of the Il21 gene, or B cells with a targeted disruption of the Il21r gene, demonstrate that IL-21 from T cells signaling through the IL-21 receptor on B cells is necessary to control chronic Plasmodium chabaudi infection. Our data uncover a mechanism by which CD4+ T cells and B cells control parasitemia during chronic erythrocytic-stage malaria through a single gene, Il21, and demonstrate the importance of this cytokine in the control of pathogens by humoral immune responses. These data are highly pertinent for designing malaria vaccines requiring long-lasting protective B-cell responses.

Author Summary

The importance of antibody and B-cell responses for control of the erythrocytic-stage of the malaria parasite, Plasmodium, was first described when immune serum, passively transferred into Plasmodium falciparum-infected children, reduced parasitemia. This was later confirmed in experimental models in which mice deficient in B cells were unable to eliminate erythrocytic-stage infections. The signals required to activate these protective
long-lasting B cell responses towards *Plasmodium* have not been investigated. IL-21 has been shown to be important for development of B-cell responses after immunization; however, a direct requirement for IL-21 in the control of infection via B-cell dependent mechanisms has never been demonstrated. In this paper, we have used mouse models of erythrocytic *P. chabaudi* and *P. yoelii* 17X(NL) infections in combination with IL-21/IL-21R deficiency to show that IL-21 from CD4+ T cells is required to eliminate *Plasmodium* infection by activating protective, long-lasting B-cell responses. Disruption of IL-21 signaling in B cells prevents the elimination of the parasite resulting in sustained high parasitemias, with no development of memory B-cells, lack of antigen-specific plasma cells and antibodies, and thus no protective immunity against a second challenge infection. Our data demonstrate the absolute requirement of IL-21 for B-cell control of this systemic infection. This has important implications for the design of vaccines against *Plasmodium*.

**Introduction**

Malaria is the leading parasitic cause of morbidity and mortality worldwide; about half of the world’s population is at risk of infection [1]. There is an urgent need for an effective vaccine able to bring about high levels of protection.

Immunity to the erythrocytic stages of malaria is thought to be primarily dependent on an antibody response. In endemic areas of *Plasmodium falciparum* transmission, there are associations between *Plasmodium*-specific antibody responses and protection against infection [2–5]. Elimination of the erythrocytic stages of *Plasmodium falciparum* in infected children can be achieved by passive transfer of immune serum [2, 6], and studies in experimental models show that B cells and antibodies are important for elimination of chronic infections, and immunity to re-infection [7, 8]. A better understanding of the signals underlying activation of protective, long lasting, B-cell responses would be of great value in malaria vaccine development.

The cytokine IL-21, produced by follicular helper CD4+ T cells (Tfh) and other cells, is important for the generation of B-cell responses in germinal centers (GC), isotype switching, affinity maturation, antibody production, and development of memory B cells (MBC) [9, 10]. However, a requirement of IL-21 for activation and maintenance of Tfh cell is still controversial [11–23]. Most of our knowledge about the role of IL-21 in humoral responses has come from studies using immunization with protein antigens, where IL-21 is critical for the development of a T-cell dependent IgG response in GCs [11, 15, 16, 21, 23, 24]. Contrary to its importance in generating B cell responses after immunization, IL-21 seems not to be necessary for all aspects of T-cell-dependent B cell responses in different infection models [14, 19, 20, 22, 25, 26].

An investigation into Tfh cell development and the role of IL-21 in malaria has not been carried out, but this would be an excellent infection model in which to determine the importance of IL-21 in protective humoral immunity to a systemic pathogen, and would shed light on the induction, control and impairment of humoral responses in malaria. Here we have used a mouse model of malaria, *Plasmodium chabaudi chabaudi* AS in C57BL/6 mice, and have shown that IL-21 and Tfh cells are prominently induced and maintained in an erythrocytic-stage infection, suggesting that this crucial element of the humoral response is not impaired. Tfh cells producing IL-21 are multifunctional, with a majority also producing IFN-γ. Importantly, IL-21 produced by CD4+ T cells, acting directly on B cells, is crucial for triggering protective long-lasting *Plasmodium*-specific IgG B cell responses that are required to control and resolve the chronic phase of erythrocytic-stage malaria infection and for immunity to re-infection.
Results

IL-21 signaling is essential to control the chronic phase of blood stage *P. chabaudi* infection

Injection of $10^5$ red blood cells (rbc) infected with *P. chabaudi* (irbc) into C57BL/6 mice gives rise to an erythrocytic infection, with an early acute parasitemia occurring at day 8 post-infection. Thereafter, the infection is rapidly controlled, reaching very low parasitemia levels by day 20 post-infection. This is followed by a chronic phase of infection, characterized by a prolonged sub-patent parasitemia with small patent recrudescence for up to 60 days before parasite elimination [27].

To explore a role for IL-21 during erythrocytic-stage *P. chabaudi* infection, we first determined the pattern of IL-21 mRNA expression in spleens of C57BL/6 mice during a *P. chabaudi* infection by real-time quantitative RT-PCR. Although IL-21 mRNA was detected over basal naïve levels as early as 2 days post-*P. chabaudi* infection, there was a striking increase in the spleen by day 7 post-infection, when IL-21 mRNA levels were approximately 130-fold higher than the basal level. IL-21 mRNA decreased thereafter, but remained higher than the basal level for at least 20 days (Fig 1 A).

We next investigated whether IL-21, or signaling through its receptor, was necessary to control a primary *P. chabaudi* infection. C57BL/6 mice carrying a targeted deletion of the *Il21* gene, or its receptor, *Il21r*, were infected as described above. They were able to control the acute phase of *P. chabaudi* infection, despite showing slightly but significantly higher peak parasitemias than infected WT C57BL/6 mice (Fig 1 B). Similar to WT C57BL/6 mice, both *Il21^−/−* and *Il21r^−/−* mice had very low parasitemias by 11–14 days post-infection. However, in stark contrast to WT mice, they developed sustained high parasitemias during the chronic phase of infection (e.g., parasitemias of 17% in *Il21^−/−* and 23% in *Il21r^−/−* mice compared with less than 0.04% in WT C57BL/6 at day 36 post-infection) (Fig 1 B). These high parasitemias were maintained in both *Il21^−/−* and *Il21r^−/−* mice at day 120 post-infection, without mortality. The non-resolving *P. chabaudi* infection was accompanied by increased anemia in both *Il21^−/−* and *Il21r^−/−* mice from days 19–22 post-infection onwards (Fig 1 C).

*P. yoelii* 17X(NL) gives rise to a non-lethal erythrocytic infection in WT C57BL/6 mice that is completely cleared after the acute phase without showing a chronic phase (S1 Fig, A and B). Similar to the *P. chabaudi* infection, both *Il21^−/−* and *Il21r^−/−* mice failed to clear a *P. yoelii* 17X (NL) erythrocytic infection, and developed sustained high parasitemias (S1 Fig, A and B). These data show that the requirement for IL-21 signaling is necessary to control infection with different *Plasmodium* species.

*P. chabaudi*-infected *Il21^−/−* and *Il21r^−/−* mice showed significantly greater spleen cellularity compared with WT C57BL/6 controls as early as 32 days post-infection, and dramatic splenomegaly at later time points (Fig 1, D and E). Despite increased anemia and splenomegaly, neither *Il21^−/−* nor *Il21r^−/−* mice had any other clinical signs. At day 32 post-infection, the numbers of Ter119+ erythrocytic cells in the spleen in the absence of IL-21 signaling were dramatically increased (Fig 1F), thus contributing to the large splenomegaly observed in *Il21^−/−* and *Il21r^−/−* mice from day 32 post-infection onwards.

In addition, at this time the numbers of NK cells, granulocytes and monocytes were greater in the *Il21r^−/−* spleens compared with WT C57BL/6 controls (S2 Fig). On the other hand, the numbers of B cells in the spleen from *Il21r^−/−* mice were substantially reduced compared to WT C57BL/6 control (S2 Fig).

Taken together, these data demonstrate a central role for IL-21 signaling in the resolution of erythrocytic-stage *P. chabaudi* and *P. yoelii* 17X(NL) infections.
IL-21 is produced by CD4+ T cells during *P. chabaudi* infection, and co-expressed with IFN-γ and IL-10

To identify which cells were responsible for the production of IL-21, intracellular cytokine staining and multiparameter flow cytometry performed on splenic cells from WT C57BL/6
mice revealed that IL-21 production was observed only in CD4+ T cells throughout the acute phase of a *P. chabaudi* infection (Fig 2, A and B). At no point during the infection was IL-21 detectable in NK cells, CD19+ cells or CD3–NK1.1– cells. In accordance with the kinetics observed for IL-21 mRNA expression (Fig 1 A), the percentage and total number of

![Flow cytometry plots showing individual examples of IL-21 expression on mononuclear cells from WT C57BL/6 and Il21−/− mice at day 8 post-infection (top row). For the gating strategy, singlet cells were first selected, followed by live cells and mononuclear cells. In the bottom row, the IL-21-producing mononuclear cells detected in WT C57BL/6 mice, identified by red dots, were overlaid on the plots corresponding to the different combinations of surface biomarkers. (B) Cumulative data showing the differential combination of expression (+) or absence of expression (−) of each surface marker (indicated in the bottom left) on IL-21-producing mononuclear cells. (C) Flow cytometry plots showing individual examples of IL-21 expression on CD3+CD4+ T cells at day 8 post-infection. (D) Cumulative data showing the percentage (left) and total numbers (right) of IL-21-producing CD4+ T cells in the spleen of WT C57BL/6 mice at different days post-infection. Data are representative of at least two independent experiments and were obtained in groups of 4–5 mice per time point. Statistical significance was obtained using the Kruskal-Wallis test comparing each time point with its respective basal level (day 0 post-infection) (*, P<0.05; **, P<0.01; *** , P<0.001); or comparing each surface marker combination with every other surface marker combination within each time point (# #, P<0.01). Bars represent median values.

doi:10.1371/journal.ppat.1004715.g002
IL-21-producing CD4+ T cells in the spleen increased early after infection, (Fig 2, C and D). Both percentages and total numbers decreased thereafter, but remained higher than basal naïve levels at least up to day 32 post-infection. By 120 days post-infection, the frequency and total numbers of IL-21-producing CD4+ T cells in the spleen were comparable to those observed in naïve WT C57BL/6 mice.

The majority of IL-21-producing CD4+ T cells in the spleens of WT C57BL/6 mice co-expressed IFN-γ; in particular at the peak of infection, when over 70% of the IL-21-producing CD4+ T cells in the spleen also expressed IFN-γ (Fig 3, A, E and F). The total number of CD4+ T cells co-expressing IL-21 and IFN-γ showed a dramatic increase by day 8 post-infection, remained high at day 15 post-infection, and decreased thereafter (Fig 3 F). Interestingly, some of the IL-21-producing CD4+ T cells expressing IFN-γ also expressed IL-10 (Fig 3, C-F). The frequency of these triple producers increased with the progression of the infection until day 32 post-infection, when a maximum of approximately 30% of IL-21-producing CD4+ T cells co-expressed IFN-γ and IL-10 (Fig 3 D and E). The highest number of IL-21-producing CD4+ T cells co-expressing IFN-γ and IL-10 was detected at day 15 post-infection (Fig 3 F). By day 120–140 post-infection, the pattern of cytokines co-expressed with IL-21 resembled that of naïve WT C57BL/6 mice (Fig 3, E and F). Altogether, these data show that CD4+ T cells are the main source of IL-21 in the spleens of WT C57BL/6 mice during P. chabaudi infection, and demonstrate the occurrence of multifunctional CD4+ T cells co-expressing IFN-γ and IL-10 together with IL-21.

Having identified CD4+ T cells as the producers of IL-21 during P. chabaudi infection, we wanted to confirm that IL-21 production by T cells was necessary to control P. chabaudi infection. To this end, we generated mixed bone marrow (BM) chimeras in which the deletion of the Il21 gene, or its receptor, was restricted to T cells (Fig 4 A). Control groups consisted of mixed BM chimeric mice reconstituted with BM obtained from WT C57BL/6 mice, and from Tcra-/- [28] and Ighm [29] mice mixed in an 80:20 ratio. Similar to Il21-/- and Il21r-/- mice, mixed BM chimeric mice bearing Il21r-/- T cells failed to control the chronic phase of infection and showed increasingly and sustained high parasitemias during this phase of infection (Fig 4 B). IL-21R signaling on T cells was not required to control P. chabaudi infection, as mixed BM chimeric mice bearing Il21r-/- T cells showed a normal course of P. chabaudi infection when compared with WT C57BL/6 mice or mixed BM chimeric control groups (Fig 4 C). Together, these data demonstrate the requirement for IL-21 production by CD4+ T cells to control chronic P. chabaudi infection.

P. chabaudi infection promotes a robust Tfh cell response, even in the absence of IL-21 signaling

Tfh cells collaborate with B cells and are considered to be critical for the development of antigen-specific B cell responses during GC reactions [9, 10]. Tfh cells are a major source of IL-21, and this cytokine has been shown to be important for Tfh cell functionality. Therefore, we assessed the numbers of Tfh cells generated during a P. chabaudi infection, whether these cells were generated, whether they were the source of IL-21, and whether IL-21 was required for their generation and maintenance.

For multiparameter flow cytometry analysis, we defined Tfh cells as CD3+CD4+CD44high CXCR5+PD-1+ (S3A Fig), and confirmed the identity of Tfh cells by intranuclear staining of the master regulator of Tfh cell differentiation, the transcription factor Bcl-6 (S3B Fig). Infection of WT C57BL/6 mice with P. chabaudi led to an increase in Tfh cells, as evinced by a greater than 14-fold and 60-fold increase in their frequency and total numbers, respectively, in the spleen, 8 days post-infection, when compared to basal levels (Fig 5, A-C). At the peak of
Fig 3. IL-21 is co-expressed with IFN-γ and IL-10 during *P. chabaudi* infection. (A-D) Flow cytometry plots showing individual examples for days 8 and 15 post-infection of different cytokine combinations studied in CD3⁺CD4⁺ T cells from the spleen of WT C57BL/6 mice. (D) IL-21-producing CD4⁺ T cells (red) overlaid on the plots corresponding to IFN-γ vs IL-10 on gated CD3⁺CD4⁺ T cells. Cumulative data showing the percentage (E) and total numbers (F) of IL-21-producing CD4⁺ T cells co-expressing IFN-γ, IL-4 and IL-10 in the spleen of WT C57BL/6 mice. The differential combination of expression (+) or absence of expression (−) of each cytokine (indicated in the bottom left) is shown for each subset at different days post-infection. Data are representative of at least
two independent experiments and were obtained in groups of 4–6 mice per time point. Statistical significance was obtained using the Kruskal-Wallis test comparing each time point, corresponding to each cytokine combination with its respective basal level (day 0 post-infection). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Bars represent median values.

doi:10.1371/journal.ppat.1004715.g003

* P. chabaudi infection, approximately 60% of the IL-21-producing CD4+ T cells in the spleen of WT C57BL/6 mice showed a Tfh cell phenotype (Fig 5, D and E). The majority of the IL-21-producing Tfh cells at the peak of P. chabaudi infection co-expressed IFN-γ (74.3±1.3%, Fig 5 F). Both the frequency and total numbers of Tfh cells in the spleen decreased at day 15 post-infection, reached basal levels by day 32 post-infection, and remained low at later time points of the study (Fig 5, A–C).

Neither IL-21, nor IL-21R, was required to generate a Tfh cell response during P. chabaudi infection, as the kinetics and magnitude of Tfh cell responses in Il21-/− and Il21r-/− was essentially similar to those observed in WT C57BL/6 mice (Fig 5, A–C). As IL-6 has also been implicated in Tfh differentiation [9], we determined whether infected Il21-/− and Il21r-/− mice could produce IL-6, which might explain their ability to generate Tfh cells. In both knockout strains, IL-6 was detected in the plasma at day 6 of infection at levels not significantly different from those of infected WT C57BL/6 controls (Fig 5 G). The slightly higher numbers of Tfh cells in Il21-/− and Il21r-/− at day 120 post-infection compared with those in WT C57BL/6 mice might have been a consequence of the on-going infection promoting continued T cell activation. In accordance with this idea, both Il21-/− and Il21r-/− mice showed higher frequencies of CD44high and PD-1+ CD4+ T cells in the spleen at day 120 post-infection when compared to WT C57BL/6 mice (frequencies CD4+CD44high of 82±5% and 62±14% for Il21-/− and Il21r-/− vs 14±2% for WT C57BL/6; frequencies CD4+PD-1+ of 74±5 and 61±7 for Il21-/− and Il21r-/− vs 8±2 for WT C57BL/6; P < 0.01, Kruskal-Wallis test). P. chabaudi infection failed to activate Tfh cells in B-cell-deficient Ighm mice (Fig 5, A–C), which is in agreement with previous findings showing a requirement for the presence of B cells [30] and direct interactions with B cells [31] for the activation of Tfh cells.

Fig 4. Mice bearing T cells deficient in IL-21 fail to control chronic P. chabaudi infection. Course of a P. chabaudi infection in mixed BM chimeric mice generated as described with the scheme in (A) and detailed in Materials and Methods and S1 Table, (B) with fully functional B cells and T cells deficient in the Il21 gene (Il21−/− T cells, closed squares), and (C) with fully functional B cells and T cells deficient in the Il21r gene (Il21r−/− T cells, closed triangles) infected with P. chabaudi. As controls, mixed BM chimeric mice with BM from Tcra−/− and Ighm mice were generated (Il21+/+ and Il21r+/+ T cells, open squares, details in S1 Table). Statistical significance was obtained using Mann Whitney U test. **, P < 0.01; ***, P < 0.001. The graphs show the mean ± SEM of the parasitemia at different time points in 7–10 mice per group. Data are representative of two independent experiments.

doi:10.1371/journal.ppat.1004715.g004
Fig 5. IL-21-producing Tfh cells are activated during acute P. chabaudi infection. (A) Flow cytometric analysis of representative naïve (top row) and infected mice (8 days post-infection, bottom row). Gates show frequency of CD3+CD4+CD44high cells expressing CXCR5 and PD-1. (B) Frequency and (C) total numbers of Tfh cells, defined as CD3+CD4+CD44highCXCR5+PD-1+, in WT C57BL/6, Il21-/-, Il21r-/- and Ighm mice. (D) Flow cytometric analysis representative of infected WT C57BL/6 mice (8 days post-infection) corresponding to IL-21 intracellular staining on CD4+ T cells (red), overlaid on side scatter light vs CD44 (left) and CXCR5 vs PD-1 (right) from CD3+CD4+ T cells. Numbers show frequency of IL-21-producing CD4+ T cells with high expression of CD44 (left), and their differential expression of CXCR5 and PD-1 (right). (E) Differential combination of expression (+) or absence of expression (-) of CD44, CXCR5 and PD-1 (bottom left) on IL-21-producing CD3+CD4+ T cells at different days post-infection in the spleen of WT C57BL/6 mice, 8 days post-P. chabaudi infection (representative of 4 mice). (F) Flow cytometric analysis of IFN-γ (green line) on CD3+CD4+CD44highCXCR5+PD-1+ IL-21 T cells from the spleen of WT C57BL/6 mice, 8 days post-P. chabaudi infection. (G) Serum IL-6 at day 6 post-P. chabaudi infection. Statistical significance was obtained using the Kruskal-Wallis test comparing each time point with its respective basal level (day 0 post-infection) (*, P < 0.05; **, P < 0.01; ***, P < 0.001), or comparing with the data obtained from the WT C57BL/6 group (#, P < 0.05; ##, P < 0.01). Bars represent median values. Data are representative of at least two independent experiments and were obtained in groups of 4–7 mice per time point.

doi:10.1371/journal.ppat.1004715.g005
These data show a strong activation of Tfh cell responses during acute *P. chabaudi* infection, which is not affected by the lack of signaling through the IL-21R. This T cell subset represents an important source of IL-21 at the peak of *P. chabaudi* infection, and co-expresses IFN-γ.

**IL-21 is required to generate *P. chabaudi*-specific B cell responses, and is necessary for protective immunity against a secondary challenge infection**

As IL-21 signaling is required to control the chronic phase of *P. chabaudi* infection and Tfh cells are an important source of IL-21, we reasoned that the lack of IL-21 signaling would impair the development of protective B cell responses and consequently prevent the resolution of the infection.

Flow cytometric analysis of the different B cell compartments in spleen and BM showed no significant differences in naïve *Il21−/−* and *Il21r−/−* mice compared with those of naïve WT C57BL/6 controls (Fig 6). At day 32 post-infection, the numbers of B cells in the spleen of *Il21−/−* and *Il21r−/−* mice were reduced compared to WT C57BL/6 controls (S2 Fig), and this was reflected in the numbers of mature (M), transitional 1 (T1) and transitional 2 (T2) B cells (Fig 6, A-D). A robust CD19+IgD−GL−7highCD38low GC B cell response in the spleen of WT C57BL/6 controls was observed at day 15 post-infection and sustained at day 32 post-infection (Fig 6, E-G). In stark contrast, both *Il21−/−* and *Il21r−/−* mice failed to generate this GC response during *P. chabaudi* infection (Fig 6, E-G). The numbers of B220+CD138+ plasmablasts in the spleen of WT C57BL/6 controls were increased at day 32 post-infection (Fig 6, H and I). Interestingly, the numbers of B220+CD138+ plasmablasts in the spleen of *Il21−/−* and *Il21r−/−* mice were similar to those of WT C57BL/6 mice (Fig 6, H and I). However, the numbers of B220+CD138high plasmablasts in BM from *Il21−/−* and *Il21r−/−* mice, and the numbers of B220+CD138+ plasma cells in BM from *Il21−/−* mice were reduced at day 32 post-infection compared to those of WT C57BL/6 controls (Fig 6, J-L).

Although there were no differences in the initial numbers of B cells, *P. chabaudi*-specific IgG antibodies of all isotypes were absent in both *Il21−/−* and *Il21r−/−* mice at all evaluated time points (Fig 7, A and B). IgM antibodies, on the other hand, were not significantly affected by the lack of IL-21 signaling (Fig 7 C). In line with the absence of IgG antibodies, there was also a loss of both *P. chabaudi*-specific IgG antibody-secreting-cells (ASC) in the BM (Fig 7 D), and of *P. chabaudi*-specific IgG MBC in the spleen (Fig 7 E) at day 32 post-infection in both *Il21−/−* and *Il21r−/−* mice when compared with WT C57BL/6 controls.

To evaluate whether IL-21 directly signaled B cells to mount an antibody response, and thus to resolve the chronic phase of *P. chabaudi* infection, we generated mixed BM chimeric mice in which a targeted deletion of the *Il21r* gene was restricted to B cells (Fig 8 A). Control groups consisted of mixed BM chimeric mice reconstituted with BM obtained from WT C57BL/6 mice, and from *Tcra−/−* [28] and *Ighm* [29] mice mixed in a 20:80 ratio. Similar to the *Il21r−/−* mice, the mixed BM chimeric mice bearing *Il21r−/−* B cells eventually developed a non-resolving chronic-stage parasitemia (Fig 8 B). Furthermore, the mixed BM chimeric mice bearing *Il21r−/−* B cells, as well as the mixed BM chimeric mice bearing *Il21−/−* T cells, but not those bearing *Il21r−/−* T cells or *Il21−/−* B cell, showed a dramatic decrease in the levels of *P. chabaudi*-specific IgG antibodies and in the numbers of *P. chabaudi*-specific IgG MBC in the spleen (Fig 8, C and D).

C57BL/6 mice develop significant immunity to a second infection with the same strain of *P. chabaudi* and are able control the challenge infection at very low parasitemias [27]. Because infected *Il21−/−* and *Il21r−/−* mice cannot make *P. chabaudi*-specific IgG responses, and in particular MBC responses, we reasoned that lack of IL-21 signaling would render these mice unable
Fig 6. Flow cytometry analysis of B cell responses during P. chabaudi infection in WT C57BL/6, Il21−/− and Il21r−/− mice. (A-D) Analysis of Mature (M) Transitional 1 (T1) and Transitional 2 (T2) on CD19+B220+ gated B cells in the spleen based on the pattern of IgD and IgM expression. (E-G) Analysis of GL-7highCD38low GC cells on CD19+IgD− gated B cells in the spleen. (H-I) Analysis of B220+CD138+ plasmablasts in the spleen. (J-L) Analysis of B220+CD138high plasmablasts and B220−CD138high plasma cells in the BM (1 femur plus 1 tibia per mouse). Statistical significance was obtained using the Kruskal-Wallis test comparing each time point with its respective basal level (day 0 post-infection) (*, P<0.05; **, P<0.01), or comparing with the data...
to control a re-infection. We therefore infected Il21−/−, Il21r−/− and WT C57BL/6 mice with 10⁵ P. chabaudi-irbc, treated them with chloroquine 30–45 days post-infection to eliminate the chronic primary infection, and re-challenged them with 10⁵ P. chabaudi-irbc of the same strain 3 weeks after drug treatment (Fig 9 A). In accordance with our previous data, WT C57BL/6 similarly treated with chloroquine during the primary chronic infection were immune to a second challenge with very low parasitemias. In stark contrast, both Il21−/− and Il21r−/− mice failed to resolve the second infection and showed sustained high parasitemias (Fig 9 B and C). Interestingly, neither Il21−/− nor Il21r−/− mice showed the peak of parasitemia characteristic of an acute primary infection after receiving the second P. chabaudi challenge, suggesting that some

Fig 7. P. chabaudi-specific IgG B-cell responses are abrogated in the absence of IL-21 signaling. (A) IgG, (B) IgG subtypes (day 32 post-infection) and (C) IgM antibodies specific for a lysate of P. chabaudi-infected rbc determined by ELISA. Antibody units (AU) were calculated based on the P. chabaudi-specific antibody levels of a hyper-immune standard plasma defined as 1000 U. In the cases where levels of antibodies were below background, arbitrary values of 2 log lower than the mean value observed in WT C57BL/6 mice were set to be able to perform the statistical test. (D) MSP1_19-specific IgG-producing ASC in BM obtained from one femur and one tibia, and (E) MBC per spleen, determined by ELISPOT 32 days post-infection. Statistical significance was obtained using the Kruskal-Wallis test comparing each time point with its respective basal level (day 0 post-infection) (*, P < 0.05; **, P < 0.01), or comparing with the data obtained from the WT C57BL/6 group (# #, P < 0.01). The Mann Whitney U test was used in the case of IgG subtypes, comparing Il21−/− vs WT C57BL/6 mice (#, P < 0.05). Bars represent median values. Data are representative of at least two independent experiments and were obtained in groups of 3–8 mice per time point.
initial immune control could take place in the absence of an IgG B-cell response (Fig 9, B and C). Similarly, Il21r−/− mice also failed to resolve a second infection with P. yoelii 17X(NL), in contrast to WT C57BL/6 controls, which controlled parasitemias at very low levels (S1B Fig).

Similar to Tfh responses during primary infection (Fig 5 A–C and Fig 9 D), Tfh responses during second P. chabaudi infection (Fig 9 E) and IFN-γ responses of CD4+ T cells during primary and second P. chabaudi infection (Fig 9 F and G) were not altered by the absence of IL-21 signaling.

These data show that IL-21 is necessary to activate P. chabaudi-specific IgG B-cell responses, by direct signaling through the IL-21R on B cells, thus resolving the chronic infection.

Moreover, IL-21 signaling is required to activate P. chabaudi-specific IgG MBC responses, and to develop immunity to homologous secondary P. chabaudi and P. yoelii 17X(NL) infections.

**Discussion**

Here we demonstrate, for the first time, a direct requirement of IL-21 signaling on B cells for the elimination of a systemic infection, and its importance in the control of chronic malaria. In the model of P. chabaudi infection in C57BL/6 mice, IL-21 produced by CD4+ T cells, predominantly Tfh cells, during the acute phase of an erythrocytic-stage P. chabaudi infection, is necessary for development of ASC, specific IgG antibodies and MBC, and to bring about the resolution of a chronic P. chabaudi infection. In a similar way, IL-21 signaling was required to control and eliminate a P. yoelii 17X(NL) infection. Our data highlight, for the first time, the importance of IL-21-dependent B-cell responses in the acquisition of immunity to re-infection and suggest that long-lived B-cell responses are required to achieve immunity to malaria re-infection.

Both Il21−/− and Il21r−/− mice failed to produce P. chabaudi-specific IgG antibodies, and did not generate P. chabaudi-specific IgG-producing MBC in the spleen or ASC in the bone.
Fig 9. Mice deficient in IL-21 signaling fail to develop immunity to a secondary *P. chabaudi* infection.

(A) Scheme describing the experimental approach. CQ = chloroquine. (B and C) *P. chabaudi*-infected mice were treated with chloroquine to eliminate parasitemia as described in the materials and methods, and re-infected with $10^5$ *P. chabaudi*-infected rbc (day 0 post-secondary infection). The graphs show the course of secondary *P. chabaudi* infection in WT C57BL/6 (black circles), *Il21*−/− (red circles) and *Il21r*−/− (brown circles) mice; course of primary infection in *Il21*−/− (gray circles) and *Il21r*−/− (gray squares) are overlaid. (D and E) Number of Tfh cells per spleen post-primary and secondary infection, respectively. (F and G) Number of IFN-$\gamma$+CD4+ T cells per spleen post-primary and secondary infection, respectively. Data are representative of two independent experiments and are obtained in groups of 3–10 mice per time point. Statistical significance was obtained using Mann Whitney U test (**, *P* < 0.01) or Kruskal-Wallis test (#, *P* < 0.05). Error bars correspond to mean ± SEM.

doi:10.1371/journal.ppat.1004715.g009
marrow showing that IL-21 is required for class switching, and demonstrating that class switching to IgG responses is required for effective control of a \textit{P. chabaudi} infection. \textit{P. chabaudi}-specific IgM responses were not altered in the absence of IL-21 signaling. IgM can be produced by short-lived plasmablasts in the spleen, which have not undergone development in GC [32], perhaps explaining why total plasmablast numbers in the spleen were unaffected by the lack of IL-21 signaling. As we show that IL-21 signaling is required to activate GC B-cell responses upon \textit{P. chabaudi} infection, we believe that IL-21 signaling is required to activate early stages of T-dependent B-cell responses to the parasites. However, we cannot rule out a direct requirement of IL-21 in the signal pathways leading to class switch recombination and MBC generation. As mixed BM chimeric mice with B cells deficient in IL-21R showed impairment of the humoral response, and did not resolve the chronic phase of \textit{P. chabaudi} infection, it appears that there is a direct requirement for IL-21 from T cells to signal through the IL-21R on B cells to induce the differentiation of B cells into plasma cells, and thereby for antibody production. Our data is in accordance with those studies showing the critical importance of IL-21 signaling in IgG responses following immunization [11, 15, 23], but contrasts with studies of other pathogens, where there are variable requirements for IL-21 signaling for B-cell responses. In LCMV- and Influenza-infected mice, the lack of IL-21 signaling results only in slight, or no alterations in induction of B-cell responses, but the IgG antibody response is poorly sustained [19, 22, 25, 26]. Despite decreased levels of IgG1, isotype-switching and GC formation are not altered in \textit{Il21r}^{-/-} mice infected with \textit{H. polygyrus} [14]. Primary B-cell responses, but not MBC responses, against live rabies virus-based vaccines, require IL-21 signaling [12]. The reasons for these differential requirements for IL-21 in the different infections/immunizations are not known. It is possible that other signals such as co-stimulation via TLR ligation, cytokines like IL-4, or strength of the BCR signal through extensive BCR cross-linking, could partially compensate for the lack of IL-21 signaling. Intrinsic differences in the antigens and co-stimulations delivered by different infections or immunizations could then differentially engage signals able to compensate different aspects of the B-cell response that would otherwise require signaling through IL-21. In this regard, signaling through TLR7 is known to be able to restore defective B-cell activation in \textit{Il21r}^{-/-} mice [11].

The impaired control of parasitemia and loss of the humoral response to \textit{P. chabaudi} in \textit{Il21}^{-/-} and \textit{Il21r}^{-/-} mice were not due to lack of development of phenotypically-defined Tfh cells. Mice lacking IL-21 or the IL-21R in all cells were able to generate WT levels of Tfh cells; and mice lacking IL-21R only in T cells also had specific B-cell responses similar to those of WT mice. The requirement of IL-21 for the generation or maintenance of Tfh cell responses is controversial. Some studies have shown that IL-21 signaling is required for development, maintenance, or functional competence [15, 16, 19–21]. However, similar to our studies, others have shown that Tfh cell responses are normal or even elevated in the complete absence of IL-21 signaling [11–14, 17, 18, 22, 23]. Thus, the requirement for IL-21 to activate Tfh responses seems to be highly dependent on the model of immunization or infection studied. In this \textit{P. chabaudi} infection, direct IL-21 signaling on T cells is not required to activate a functional Tfh program. It is possible that IL-6, which we show here is produced at levels similar to those of infected WT mice, compensates for the lack of IL-21 in the generation of Tfh cells, as has been described [13, 16, 33, 34].

CD8$^{+}$ T cells have been shown to require IL-21 for protective responses in chronic viral infections in humans and mice [22, 25, 26, 35–37], and are known to play some role in controlling erythrocytic-stage \textit{Plasmodium} infections in mice [38–42]. Our data rule out a mechanism by which IL-21 acts on or via CD8$^{+}$ T cells to resolve the chronic \textit{P. chabaudi} infection, since, in mixed BM chimeric mice in which there is a deficiency of IL-21R only in T cells, there was no exacerbation of the chronic infection.
Despite the failure of \( I_{21}^{-/-} \) and \( I_{21r}^{-/-} \) mice to resolve their chronic infection, they did not succumb to a fulminating parasitemia within the 100–150 days of the study. One possible factor that may limit the chronic parasitemia is the preference of \( P. \) chabaudi for mature rbc [43]. The presence of large numbers of Ter119+ rbc in the spleens of \( I_{21}^{-/-} \) and \( I_{21r}^{-/-} \) mice indicates increased hematopoiesis in response to anemia, presumably leading to production of many new rbc, which then controls the level of parasitemia. In addition, there are likely to be numerous B-cell-independent innate effector mechanisms activated, which could partially control parasitemia, but unable to completely clear the infection by themselves. Different from infections in \( I_{21}^{-/-} \) and \( I_{21r}^{-/-} \) mice, mixed BM chimeric mice with B cells deficient in IL-21R did not show a significant difference in relapsing parasitemia compared to WT C57BL/6 mice until days 70–80 post-infection. The higher variability in the parasitemias in these mixed BM chimeric mice compared to \( I_{21r}^{-/-} \) late in infection may reflect B-cell-independent alternate mechanisms, which require IL-21. In general agreement with this idea, IL-21 has been shown to be involved in activation of macrophages and NK cells [44], both cell types implicated in the control of \( P. \) falciparum infection [45].

Previous studies have shown that Th1, Th2 and Th17 CD4+ T cell subsets can also produce IL-21 [9], and that Tfh cells can express cytokines characteristic of Th1/Th2/Th17 subsets [46]. This suggests either that other subsets of CD4+ T cells can produce IL-21, or that Th1/Th2/Th17 subsets activated in infections can acquire an additional Tfh phenotype. The generation of different CD4+ T cell subsets during infections is a very dynamic process, and activated CD4+ T cells, including Tfh cells, show substantial plasticity with overlapping phenotypes [47]. In the case of \( P. \) chabaudi infection, IL-21 production by CD4+ T cells was strongly linked to that of IFN-\( \gamma \), the hallmark cytokine of Th1 CD4+ T cells, reflecting the strong bias to a Th1 response during acute \( P. \) chabaudi infection. We found no IL-4/IL-21 double-producing cells, and there is little induction of IL-17 in the spleens of \( P. \) chabaudi-infected mice [48]. Later in the course of \( P. \) chabaudi infection (13–15 days), we observed the appearance of splenic CD4+ T cells co-expressing IL-21, IFN-\( \gamma \) and IL-10. IL-10 may have been induced in these cells in order to regulate the inflammatory response and thus immune-mediated pathology, as we have shown previously [49, 50].

IL-21-producing CD4+ T cells are present in peripheral blood mononuclear cells from malaria-exposed immune adults [51, 52] and correlate with \( P. \) falciparum-specific IgG antibodies in children with acute \( falciparum \) malaria [53]. These observations encourage us to believe that use of the mouse model of \( P. \) chabaudi is a valid approach to dissect the regulation and role of IL-21, Tfh and B-cell responses, which is also relevant to other infections dependent on humoral immunity for their elimination.

In summary, we show that the absence of IL-21 signaling on B cells results in a loss of capacity to activate \( P. \) chabaudi-specific IgG antibodies and memory B cells, resulting in a failure to resolve a chronic erythrocytic-stage infection with \( P. \) chabaudi and an inability to control a secondary challenge infection. This important immune mechanism should receive particular attention when exploring novel vaccine strategies.

Materials and Methods

Ethics statement

All animal experiments were approved by the MRC NIMR institutional Ethical Review Panel and carried out according to UK National guidelines (Scientific Procedures) Act 1986 under license PPL80/2385 approved by the British Home Office.
Mice
C57BL/6, Ighm\(^{-/-}\) [29], Tcra\(^{-/-}\) [28] and Rag2\(^{-/-}\) [54] mouse strains were bred in the specific pathogen-free facilities of the MRC NIMR and were backcrossed for at least 10 generations onto NIMR C57BL/6 mice. Mice with a targeted deletion of the Il21 gene, originally from NIH MMRRRC (F2 129/ SvEvBrd x C57BL6/J), were obtained from Manfred Kopf, Institute for Molecular Health Sciences, Zürich, Switzerland. They were backcrossed 3 generations to C57BL/6J at the Garvan Institute, Sydney, and then backcrossed for 5 generations by Manfred Kopf and a further 3 generations onto NIMR C57BL/6 (N7) were a kind gift from Manfred Kopf [55], and were further backcrossed 3 times onto NIMR C57BL/6. In all experiments, NIMR C57BL/6 bred in the same animal house were used as controls. From a panel of 768 SNPs, NIMR C57BL/6 and C57BL/6/J mice differ only by 2 SNPs; one each on chromosomes 2 and 12.

Mixed BM chimeras
The Il21\(^{-/-}\) and Il21r\(^{-/-}\) mice were crossed with Ighm and Tcra\(^{-/-}\) to obtain double knockout strains Ighm Il21\(^{-/-}\), Ighm Il21r\(^{-/-}\), Tcra\(^{-/-}\) Il21\(^{-/-}\), and Tcra\(^{-/-}\) Il21r\(^{-/-}\). To generate mixed BM chimeric mice in which either B or T cells were deficient in the expression of IL-21 or IL-21R, femurs and tibias from donor mice were excised and cleaned of flesh using forceps and scalpel, and BM was obtained by flushing out with IMDM supplemented with 2 mM L-glutamine, 0.5 mM sodium pyruvate, 100 U penicillin, 100 mg streptomycin, 6 mM Hepes buffer, and 50 mM 2-ME (all from Gibco, Invitrogen), using a syringe with a needle. Thereafter, single BM cell suspensions were obtained by mashing through a 70 μm filter mesh, further sieved through 40 μm filter mesh and washed once. Live cells were resuspended in sodium chloride solution 0.9% (Sigma) at 4x10\(^6\) cells/200 μl. Rag2\(^{-/-}\) mice were sub-lethally irradiated (5 Gy) using a \(^{[137}\)Cs source and reconstituted less than 24hr after irradiation by i.v. injections of different combinations of donor BM cells (S1 Table and S4 Fig). Recipient mice were maintained on acidified drinking water and analyzed for reconstitution after 8 weeks. Only mixed BM chimeric mice showing frequencies of T and B cells similar to those of WT C57BL/6 control mice were included in experiments.

Infection of mice with \(P.\) chabaudi and \(P.\) yoelii
Mice were infected with 10\(^5\) \(P.\) chabaudi chabaudi AS–infected or 10\(^3\) \(P.\) yoelii 17X(NL)-infected rbc by i.p. injections, and parasitemias monitored by Giemsa-stained blood films, as previously described [56]. The total number of rbc and hemoglobin concentrations were determined using a Vetscan (Abaxis), and body ventral temperature was measured using a Mini-Temp MT6 infrared thermometer (Raytek).

Drug treatment
Drug-mediated elimination of \(P.\) chabaudi infection in Il21\(^{-/-}\), Il21r\(^{-/-}\) and WT C57BL/6 mice was accomplished with 10 i.p. injections of 40 mg chloroquine (Sigma)/kg body weight in 0.9% sodium chloride solution given in 10 consecutive days, starting on day 30–45 post-primary infection. Drug-mediated elimination of \(P.\) yoelii in Il21r\(^{-/-}\) and WT C57BL/6 was accomplished with chloroquine given in drinking water (600mg/L) during 6 consecutive days, followed by 3 i.p. injections of 0.25 mg pyrimethamine (Sigma) given in 3 consecutive days, followed by 3 i.p. injections of 1.25 mg of artemisin (Pharbaco) given in 3 consecutive days. Elimination of parasitemia was monitored by Giemsa-stained blood films and, in the case of \(P.\) chabaudi infection, to verify complete elimination of parasitemia after chloroquine.
treatment, 50 μl of blood were obtained from each mouse, diluted in 350 μl Kreb’s saline containing glucose (11 mM) and heparin (50 mU) and subinoculated into Rag2−/− mice. Giemsa-stained thin blood films from the recipient Rag2−/− mice were monitored for 3 weeks [27]. A second infection of 10^5 P. yoelii-infected rbc was given to IL21r−/− and WT C57BL/6 control mice 3 days after the last artesunate injection.

**Quantitative real-time PCR**

Expression of IL-21 mRNA was measured as previously described [48]. Briefly, total RNA was extracted from splenocytes from uninfected and P. chabaudi-infected C57BL/6 mice with TRIzol reagent (Life Technologies), reverse transcribed, and IL-21 mRNA was measured using real-time quantitative PCR with the primers, forward TCATCATTGACCTCGTGGCCC and reverse ATCGTACTTCTCCACTTGCAATCCC.

**Flow cytometry**

Spleens were dissected and single cell suspension was obtained by mashing the organs through a 70 μm filter mesh in HBSS (Gibco, Invitrogen). After removal of rbc by treatment with lysing buffer (Sigma), the remaining cells were resuspended in complete IMDM [IMDM supplemented with 10% FBS Serum Gold (PAA Laboratories, GE Healthcare), 2 mM L-glutamine, 0.5 mM sodium pyruvate, 100 U penicillin, 100 mg streptomycin, 6 mM Hepes buffer, and 50 mM 2-ME (all from Gibco, Invitrogen)] and viable cells were counted using trypan blue exclusion (Sigma) and a hemocytometer. Cells were then resuspended in PBS containing 2% FBS, 0.1% N2N3 (staining buffer), with the monoclonal anti-mouse CD16/32 [24G2, [57]] to block Fc-mediated binding of antibodies. To identify Tfh cells, 2x10^6 cells were first incubated with biotin anti-CXCR5 in complete IMDM (BD Pharmingen), washed twice with staining buffer, resuspended in PBS and incubated with appropriate dilutions of PE or APC streptavidin, PE/Cy7 anti-PD-1, APC/Cy7 anti-CD4, FITC or PerCP/Cy5.5 anti-CD44 and APC or Pacific Blue anti-CD3e (Biolegend). Cells were fixed with 2% paraformaldehyde and stored in staining buffer at 4°C until acquisition. For B cell analysis, spleens and BM (1 femur plus 1 tibia) were prepared as described above, and 2x10^6 cells were first incubated with anti-mouse CD16/32, followed by surface staining with different combinations of BV605 or BV785 anti-CD19, APC or PE/Cy7 anti-B220, BV421 anti-IgD, PerCP/Cy5.5 anti-IgM (all from Biolegend), FITC anti-GL-7, PE anti-CD138 (BD Pharmingen) and APC anti-CD38 (eBioscience), and acquired after two washes with PBS. To identify the different cell populations in the spleen, 2x10^6 cells were first incubated with anti-mouse CD16/32, followed by surface staining with different combinations of BV785 anti-CD19, BV711 anti-NK1.1, BV650 anti-CD8, BV605 anti-CD4, BV421 anti-γδTCR, PerCP/Cy5.5 anti-Ly6G, FITC anti-MHCII, PE anti-Ly6C, APC/Cy7 anti-Ter119, alexa fluor 700 anti-CD3 and alexa fluor 647 anti-CD11c (all from Biolegend), and acquired after two washes with PBS.

For intracellular cytokine staining, cells were stimulated for 5h in complete IMDM with PMA (50 ng/mL; Sigma), Ionomycin (500 ng/mL; Sigma), and Brefeldin A (10 mg/mL; Sigma), and surface stained as described above. Intracellular staining for IL-21-producing Tfh cells was performed as described [58–60]. Briefly, cells were fixed in 2% paraformaldehyde and stored in staining buffer overnight at 4°C, permeabilized in Perm/Wash buffer (BD Pharmingen), and incubated in Perm/Wash with recombinant mouse IL-21 receptor/human Fc chimera (5mg/mL; R&D Systems). Cells were then stained with R-Phycocerythrin-conjugated AffiniPure F(ab')2 Fragment Goat Anti-Human IgG (Jackson ImmunoResearch). For the study of cytokines co-expressed with IL-21, cells were further stained with PE/Cy7 anti-IFN-γ, FITC anti-IL-10, alexa fluor 647 anti-IL-4 (all from Biolegend) or FITC anti-IFN-γ (eBioscience). Intranuclear
staining of Bcl-6 was performed using PE anti-Bcl-6 (eBioscience) and the Foxp3/Transcription Factor Staining Buffer Set (eBioscience), following manufacturer’s manual. Cells were acquired on CyAn ADP (Beckman Coulter), BD FACSVerse, BD LSRII or BD LSRFortessa X-20 (BD Biosciences) flow cytometers. Dead cells were excluded by staining with LIVE/DEAD Fixable Aqua or Blue stain (Invitrogen). Singlets were selected based on FCS-A vs FCS-W and further based on SSC-A vs SSC-W. “Fluorescence minus one” (FMO) controls, in combination with isotype controls, were used to set the thresholds for positive/negative events. Analysis was performed with FlowJo software version 9.6 or higher (Tree Star).

ELISPOT assays

ELISPOTs to measure ex-vivo frequencies of P. chabaudi-specific ASC in BM and MBC in spleen were performed as previously described [61]. Cells were incubated for 5h on 96-wells Multiscreen-HA filter plates (Millipore) coated with the C-terminal 21kDa part of P. chabaudi merozoite surface protein 1 (MSP121), prepared as described [62], to measure the frequency of MSP121-specific ASC, or coated with affinity-purified goat anti-mouse IgG (Sigma), to measure the frequency of total IgG ASC. Spots were enumerated with an Immunospot analyzer (CTL, Germany).

For MBC ELISPOTs, spleen cells were obtained by mashing the spleens through a 70 μm filter strainer, and rbc were eliminated by treatment with lysing buffer (Sigma). Cells were polyclonally activated by incubation for 6 days in flat-bottomed 96-well plates in the presence of irradiated feeder splenocytes, LPS, and supernatant from concanavalin A-stimulated C57BL/6 spleen cells. Four-fold dilutions of splenocytes were tested in replicates of 22 wells each. Cells were then transferred to antigen-coated 96-well Multiscreen-HA filter plates (Millipore) for ASC ELISPOT performed as described above. Precursor frequencies were calculated with ELDA software [63].

ELISA

Serum samples were obtained periodically after P. chabaudi infection by bleeding the mice from the tail vein. MSP121 and whole parasite lysate were generated and used in ELISAs to measure specific IgM, IgG and IgG subclasses, as previously described [64].

Statistical analysis

Statistical analysis was performed using Mann Whitney U test or Kruskal-Wallis test on Prism software version 6 (GraphPad). P<0.05 was accepted as a statistically significant difference.

Accession numbers

- *Ighm* Ig mu chain C region [*Mus musculus*]; Gene ID: 102641210; Uniprot ID: P01872
- *Tcra* T-cell receptor alpha chain C region [*Mus musculus*]; Gene ID: 21473; Uniprot ID: P01849
- *Rag2* V(D)J recombination-activating protein 2 [*Mus musculus*]; Gene ID: 19374; UniProt ID: P21784
- *Il21* Interleukin-21 [*Mus musculus*]; Gene ID: 60505; Uniprot ID: Q9ES17
- *Il21r* Interleukin-21 receptor [*Mus musculus*]; Gene ID: 60505; Uniprot ID: Q9JHX3
- *Bcl6* B cell leukemia/lymphoma 6 [*Mus musculus*]; Gene ID: 12053; Uniprot ID: P41183
- **CD16** Low affinity immunoglobulin gamma Fc region receptor III [*Mus musculus*]; Gene ID: 14131; Uniprot ID: P08508
- **CD32** Low affinity immunoglobulin gamma Fc region receptor II [*Mus musculus*]; Gene ID: 14130; Uniprot ID: P08101
- **CXCR5** chemokine (C-X-C motif) receptor 5 [*Mus musculus*]; Gene ID: 12145; UniProt ID: Q04683
- **IFNg** Interferon gamma [*Mus musculus*]; Gene ID: 15978; Uniprot ID: P01580
- **Il10** Interleukin-10 [*Mus musculus*]; Gene ID: 16153; Uniprot ID: P18893
- **TLR7** Toll like receptor 7 [*Mus musculus*]; Gene ID: 170743; Uniprot ID: Q548J0
- **Il4** Interleukin-4 [*Mus musculus*]; Gene ID: 16189; Uniprot ID: P07750
- **CD38** antigen [*Mus musculus*]; Gene ID: 12494; Uniprot ID: P56528
- **CD19** antigen [*Mus musculus*]; Gene ID: 12478; Uniprot ID: P25918
- **B220** protein tyrosine phosphatase, receptor type, C [*Mus musculus*]; Gene ID: 19264; Uniprot ID: P06800
- **Ter119** lymphocyte antigen 76 [*Mus musculus*]; Gene ID: 104231

**Supporting Information**

**S1 Fig. P. yoelii infection in mice deficient in IL-21 signaling.** Course of primary (A) and secondary (B) *P. yoelii* 17X(NL) infection in WT C57BL/6 (black circles), *Il21r−/−* (open circles) and *Il21r−/−* (open squares). Statistical significance was obtained using Mann Whitney U test (*, *P* < 0.05; **, *P* < 0.01).

(TIF)

**S2 Fig. Cellular composition of the spleen during chronic *P. chabaudi* infection.** (A) Numbers of different cell populations in the spleen of *Il21r−/−* and WT C57BL/6 mice at day 32 post-infection. (B) Flow cytometry gating strategy applied to identify the different cell populations. Statistical significance was obtained using Mann Whitney U test (*, *P* < 0.05). (TIF)

**S3 Fig. Gating strategy applied to identify Tfh cells in the spleen by flow cytometry.** (A) Surface staining. (B) Intranuclear staining of Bcl-6.

(TIF)

**S4 Fig. Gating strategy applied to verify normal reconstitution in blood from mixed BM marrow chimeric mice by flow cytometry.** Peripheral blood was obtained from all mixed BM chimeric mice used for experiments and analyzed by flow cytometry before infection. (A) Individual examples showing the gating strategy. (B) Frequencies of CD19+ B cells. (C) Frequencies of CD3+CD4+ T cells. (D) Frequencies of CD3+CD8+ T cells. No significant differences between the experimental groups and their corresponding control groups were obtained using Mann Whitney U test (P<0.05).

(TIF)

**S1 Table.** Combination of BM cells obtained from different donors used to reconstitute *Rag2−/−* mice and generate the mixed BM chimeric groups used to study the deficiency of
IL-21 and IL-21R restricted to T or B cells during *P. chabaudi* infection.

(DOCX)

**Acknowledgments**

We thank Anne O’Garra, George Kassiotis and Mark Wilson for their helpful comments and critical reading of the manuscript. We thank Minh Phuong Nguyen for skilled technical assistance, Sola Ogun for advice on *P. yoelii* infections, and Edina Schweighoffer for advice on B-cell flow cytometry analysis. We are grateful for assistance from the Division of Biological Services, the Flow Cytometry facility and PhotoGraphics at NIMR. We thank Akira Suto, Shingo Nakayama, Hiroshi Nakajima, and John O’Shea for sharing their protocols for IL-21 intracellular staining, and Keiji Hirota and Gitta Stockinger for sharing their protocols for Tfh cells staining.

**Author Contributions**

Conceived and designed the experiments: DPM DHLN APFdR JL. Performed the experiments: DPM DHLN APFdR SM BMG JS GK. Analyzed the data: DPM DHLN APFdR BMG JS. Contributed reagents/materials/analysis tools: JL. Wrote the paper: DPM JL.

**References**

1. World Health Organization. (2013) World Malaria Report. 2013:1–286.
2. Cohen S, McGregor IA, and Carrington S. (1961) Gamma-globulin and acquired immunity to human malaria. Nature. 192:733–7. PMID: 13880318
3. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, et al. (2000) A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med. 6(6):689–92. PMID: 10835687
4. Fowkes FJI, Richards JS, Simpson JA, and Beeson JG. (2010) The relationship between anti-merozoite antibodies and incidence of *Plasmodium falciparum* malaria: A systematic review and meta-analysis. PLoS Med. 7(1):e1000218. doi: 10.1371/journal.pmed.1000218 PMID: 20098724
5. Osier FHA, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and magnitude of antibody responses to multiple *Plasmodium falciparum* merozoite antigens are associated with protection from clinical malaria. Infect Immun. 76(5):2240–8. doi: 10.1128/IAI.01585-07 PMID: 18316390
6. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, et al. (1991) Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. 45(3):297–308. PMID: 1928564
7. Burns JM Jr., Dunn PD, and Russo DM. (1997) Protective immunity against *Plasmodium yoelii* malaria induced by immunization with particulate blood-stage antigens. Infect Immun. 65(8):3138–45. PMID: 9234766
8. von der Weid T, Honavar N, and Langhorne J. (1996) Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J Immunol. 156(7):2510–6. PMID: 8786312
9. Crotty S. (2011) Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 29:621–63. doi: 10.1146/annurev-immunol-031210-101400 PMID: 21314428
10. Linterman MA, and Vinuesa CG. (2010) T follicular helper cells during immunity and tolerance. Prog Mol Biol Transl Sci. 92:207–48. doi: 10.1016/S1777-1173(10)90200-7 PMID: 20800823
11. Bessa J, Kopf M, and Bachmann MF. (2010) Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol. 184(9):4615–9. doi: 10.4049/jimmunol.0903949 PMID: 20368279
12. Dorfmeier CL, Tzvetkov EP, Gatt A, and McGettigan JP. (2013) Investigating the Role for IL-21 in Rabies Virus Vaccine-induced Immunity. PLoS Neg Trop Dis. 7(3):e2129. doi: 10.1371/journal.pntd.0002129 PMID: 23516600
13. Eto D, Lao C, DiToro D, Barnett B, Escobar TC, et al. (2011) IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PloS One. 6(3):e17739. doi: 10.1371/journal.pone.0017739 PMID: 21423809
14. King IL, Mohrs K, and Mohrs M. (2010) A nonredundant role for IL-21 receptor signaling in plasma cell differentiation and protective type 2 immunity against gastrointestinal helminth infection. J Immunol. 185(10):6138–45. doi: 10.4049/jimmunol.1001703 PMID: 20926797

15. Linterman MA, Beaton L, Yu D, Ramiscal RR, Srivastava M, et al. (2010) IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med. 207(2):353–63. doi: 10.1084/jem.20091738 PMID: 20142249

16. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, et al. (2008) Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity. 29 (1):138–49. doi: 10.1016/j.immuni.2008.05.009 PMID: 18599325

17. Phares TW, DiSano KD, Hinton DR, Hwang M, Zajac AJ, et al. (2013) IL-21 optimizes T cell and humoral responses in the central nervous system during viral encephalitis. J Neuroimmunol. 263(1–2):43–54. doi: 10.1016/j.jneuroim.2013.08.007 PMID: 24035008

18. Rankin AL, MacLeod H, Keegan S, Andreyeva T, Lowe L, et al. (2011) IL-21 receptor is critical for the development of memory B cell responses. J Immunol. 186(2):667–74. doi: 10.4049/jimmunol.0903207 PMID: 21169545

19. Rasheed MAU, Latner DR, Aubert RD, Gourley T, Spolski R, et al. (2013) Interleukin-21 on T cells is critical for sustained functionality and control of chronic viral infection. J Exp Med. 207(2):657–68. doi: 10.1084/jem.20091777 PMID: 20142430

20. Yi JS, Du M, and Zajac AJ. (2009) A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection. Science. 324(5934):1572–6. doi: 10.1126/science.1175194 PMID: 19443735

21. Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, et al. (2008) A fundamental role for interleukin-21 in the generation of virus-specific long-lived plasma cells. J Virol. 82(7):4231–9. doi: 10.1128/JVI.00017-08 PMID: 18599325

22. Yi JS, Du M, and Zajac AJ. (2009) A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection. Science. 324(5934):1572–6. doi: 10.1126/science.1175194 PMID: 19443735

23. Zotos D, Coquet JM, Zhang Y, Light A, D’Costa K, et al. (2010) IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med. 207(2):353–68. doi: 10.1084/jem.20091777 PMID: 20142430

24. Ozaki K, Spolski R, Feng C, Qi C, Cheng J, Sher A, et al. (2002) A Critical Role for IL-21 in Regulating Immunoglobulin Production. Science. 298(5598):1630–4. PMID: 12446913

25. Elsaesser H, Sauer K, and Brooks DG. (2009) IL-21 is required to control chronic viral infection. Science. 324(5934):1569–72. doi: 10.1126/science.1174182 PMID: 19478140

26. Stumhofer JS, Silver JS, and Hunter CA. (2013) IL-21 is Required for Optimal Antibody Production and T Cell Responses during Chronic Toxoplasma gondii Infection. PloS One. 8(5):e62889. doi: 10.1371/journal.pone.0062889 PMID: 23667536

27. Smith KG, Hewitson TD, Nossal GJ, Tarlinton DM. (1996) The phenotype and fate of the antibody-forming cells of the splenic foci. Eur. J. Immunol. 26:444–48. PMID: 8617316

28. Karnowski A, Chevrier S, Belz GT, Mount A, Emslie D, et al. (2012) B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J Exp Med. 209(11):2049–64. doi: 10.1084/jem.20111504 PMID: 23045607

29. Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, et al. (2009) Bö cells mediate the development of T follicular helper cells. Science. 325(5943):1001–5. doi: 10.1126/science.1176676 PMID: 19628815
35. Barker BR, Gladstone MN, Gillard GO, Panas MW, and Letvin NL. (2010) Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses. Eur J Immunol. 40(11):3085–96. doi: 10.1002/eji.200939939 PMID: 21061439

36. Li L, Liu M, Cheng L-W, Gao X-Y, Fu J-J, et al. (2013) HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand J Immunol. 78(5):439–46. doi: 10.1111/sji.12099 PMID: 23957859

37. Williams LD, Bansal A, Sabbaj S, Heath SL, Song W, et al. (2011) Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers. J Virol. 85(5):2316–24. doi: 10.1128/JVI.01476-10 PMID: 21159862

38. Horne-Debets JM, Faleiro R, Karunarathne DS, Liu XQ, Lineburg KE, et al. (2010) Critical role for IL-21 in both CD8+ T Cells Drives Chronic Malaria. Cell Rep. 5(5):1204–13. doi: 10.1016/j.celrep.2013.11.002 PMID: 24316071

39. Imai T, Shen J, Chou B, Duan X, Tu L, et al. (2010) Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with *Plasmodium yoelii* 17XL strain. Eur J Immunol. 40(4):1053–61. doi: 10.1002/eji.200939525 PMID: 20101613

40. Mogil RJ, Patton CL, and Green DR. (1987) Cellular subsets involved in cell-mediated immunity to murine *Plasmodium yoelii* 17X malaria. J Immunol. 138(6):1933–9. PMID: 3102605

41. Podoba JE, and Stevenson MM. (1991) CD4+ and CD8+ T lymphocytes both contribute to acquired immunity to blood-stage *Plasmodium chabaudi* A/S. Infect Immun. 59(1):51–8. PMID: 1898902

42. Süss G, Eichmann K, Kury E, Linke A, and Langhorne J. (1988) Roles of CD4+ and CD8-bearing T lymphocytes in the immune response to the erythrocytic stages of *Plasmodium chabaudi*. Infect Immun. 56(12):3081–8. PMID: 2903123

43. Carter R, and Walliker D. (1975) New observations on the malaria parasites of rodents of the Central African Republic—*Plasmodium vinckei petteri* subsp. nov. and *Plasmodium chabaudi* Landau, 1965. Ann Trop Med Parasitol. 69(2):187–96. PMID: 1155987

44. Yi JS, Cox MA, Zajac AJ. (2010) Interleukin-21: a multifunctional regulator of immunity to infections. Microbes Infect. 12(14–15):1111–9. doi: 10.1016/j.micinf.2010.07.015 PMID: 20691803

45. Liehl P, Mota MM. (2012) Innate recognition of malarial parasites by mammalian hosts. Int J Parasitol. 42(6):557–6. doi: 10.1016/j.ijpara.2012.04.006 PMID: 22543040

46. Cannons JL, Lu KT, and Schwartzberg PL. (2013) T follicular helper cell diversity and plasticity. Trends Immunol. 34(5):200–6. doi: 10.1016/j.it.2013.01.001 PMID: 23395212

47. Nakayamada S, Takahashi H, Kanno Y, and O'Shea JJ. (2012) Helper T cell diversity and plasticity. Curr Opin Immunol. 24(3):297–302. doi: 10.1016/j.coi.2012.01.014 PMID: 22341735

48. Mastelic B, do Rosario APF, Veldhoen M, Renaud JC, Jarra W, et al. (2012) IL-22 Protects Against Liver Pathology and Lethality of an Experimental Blood-Stage Malaria Infection. Front Immunol. 3:252. doi: 10.3389/fimmu.2012.00252

49. Freitas do Rosário AP, Lamb T, Spence P, Stephens R, Lang A, et al. (2012) IL-27 promotes IL-10 production by effector Th1 CD4+ T cells: a critical mechanism for protection from severe immunopathology during malaria infection. J Immunol. 188(3):1178–83. doi: 10.4049/jimmunol.1102755 PMID: 22205023

50. Li C, Corraliza I, and Langhorne J. (1999) Defect in Interleukin-10 Leads to Enhanced Malarial Disease in *Plasmodium chabaudi chabaudi* Infection in Mice. Infect Immun. 67:4453–45. PMID: 10456684

51. Mewono L, Agnandji ST, Matondo Maya DW, Mouima A-MN, Iroungou BA, et al. (2009) Malaria antigen-mediated enhancement of interleukin-21 responses of peripheral blood mononuclear cells in African adults. Exp Parasitol. 122(1):37–40. doi: 10.1016/j.exppara.2009.01.007 PMID: 19545527

52. Roetynck S, Olotu A, Simam J, Marsh K, Stockinger B, et al. (2013) Phenotypic and functional profiling of CD4 T cell compartment in distinct populations of healthy adults with different antigenic exposure. PLoS One. 8(1):e55195. doi: 10.1371/journal.pone.0055195 PMID: 23383106

53. Mewono L, Matondo Maya DW, Matissegui P-B, Agnandji ST, Kendjo E, et al. (2008) Interleukin-21 is associated with IgG1 and IgG3 antibodies to erythrocyte-binding antigen-175 peptide 4 of *Plasmodium falciparum* in Gabonese children with acute falciparum malaria. Eur Cytokine Netw. 19(1):30–5. doi: 10.1080/10440500801909491 PMID: 18989650

54. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, et al. (1992) RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68(5):855–67. PMID: 1547487

55. Fröhlich A, Marsland BJ, Sonderregger I, Kurrer M, Hodge MR, et al. (2007) IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood. 109(5):2023–31. PMID: 17077330
56. Cadman ET, Abdallah AY, Voisine C, Sponaas A-M, Corran P, et al. (2008) Alterations of splenic architecture in malaria are induced independently of Toll-like receptors 2, 4, and 9 or MyD88 and may affect antibody affinity. Infect Immun. 76(9):3924–31. doi: 10.1128/IAI.00372-08 PMID: 18559428

57. Unkeless JC. (1979) Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med. 150(3):580–96. PMID: 90108

58. Hiramatsu Y, Suto A, Kashiwakuma D, Kanari H, Kagami S-i, et al. (2010) c-Maf activates the promoter and enhancer of the IL-21 gene, and TGF-beta inhibits c-Maf-induced IL-21 production in CD4+ T cells. J Leukoc Biol. 87(4):703–12. doi: 10.1189/jlb.0909639 PMID: 20042469

59. Kashiwakuma D, Suto A, Hiramatsu Y, Ikeda K, Takatori H, et al. (2010) B and T lymphocyte attenuator suppresses IL-21 production from follicular Th cells and subsequent humoral immune responses. J Immunol. 185(5):2730–6. doi: 10.4049/jimmunol.0903839 PMID: 20660710

60. Nakayamada S, Kanno Y, Takahashi H, Jankovic D, Lu KT, et al. (2011) Early Th1 Cell Differentiation Is Marked by a Tfh Cell-like Transition. Immunity. 35(6):919–31. doi: 10.1016/j.immuni.2011.11.012 PMID: 22195747

61. Ndungu FM, Cadman ET, Coulcher J, Nduati E, Couper E, et al. (2009) Functional Memory B Cells and Long-Lived Plasma Cells Are Generated after a Single Plasmodium chabaudi Infection in Mice. PLoS Pathog. 5(12):e1000690. doi: 10.1371/journal.ppat.1000690 PMID: 20011127

62. Hensmann M, Li C, Moss C, Lindo V, Greer F, et al. (2004) Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. Eur J Immunol. 34(3):639–48. PMID: 14991593

63. Hu Y, and Smyth G. (2009) ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 347(1–2):70–8. doi: 10.1016/j.jim.2009.05.013 PMID: 19520083

64. Quin SJ, and Langhorne J. (2001) Different regions of the malaria merozoite surface protein 1 of Plasmodium chabaudi elicit distinct T-cell and antibody isotype responses. Infect Immun. 69(4):2245–51. PMID: 11254580